SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 25, 2019
DECIPHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
200 Smith Street
|(Address of registrants principal executive office)||(Zip code)|
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class
Name of exchange
on which registered
|Common Stock, $0.01 Par Value||DCPH||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
(d) On November 25, 2019, the Board of Directors (the Board) of Deciphera Pharmaceuticals, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Frank S. Friedman to the Board, effective November 25, 2019. Mr. Friedman will serve as a Class I director of the Company, to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2020 or until his earlier death, resignation or removal.
Pursuant to the Companys Non-Employee Director Compensation Policy (the Policy), the Board granted Mr. Friedman an option to purchase 24,000 shares of the Companys common stock at an exercise price equal to the closing market price per share of the Companys common stock on the NASDAQ Stock Market on the date of grant. The options will vest in equal monthly installments over a three-year period, subject to Mr. Friedmans continued service on the Board.
Mr. Friedman has entered into the Companys standard form of indemnification agreement, which is filed as Exhibit 10.4 to Amendment No. 3 to the Companys Registration Statement on Form S-1 filed on September 22, 2017.
There are no arrangements or understandings between Mr. Friedman and any other person pursuant to which Mr. Friedman was appointed as a member of the Board. There are no family relationships between Mr. Friedman, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr. Friedman, on the one hand, and the Company, on the other.
(b) On November 25, 2019, Michael Ross, Ph.D. provided the Company with notice of his resignation from the Board of Directors of the Company, effective as of November 26, 2019. Dr. Rosss resignation was voluntary and not the result of any dispute or disagreement with the operations, policies or practices of the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 26, 2019||DECIPHERA PHARMACEUTICALS, INC.|
|Steven L. Hoerter|
|President and Chief Executive Officer|